Abstract: Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimer's disease and Parkinson's disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Type:
Grant
Filed:
December 4, 2017
Date of Patent:
November 16, 2021
Assignee:
Lancaster University Business Enterprises Limited
Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Type:
Grant
Filed:
June 11, 2018
Date of Patent:
November 9, 2021
Assignee:
Novo Nordisk A/S
Inventors:
Andreas Vegge, Susanne Scheele, Simon Bjerregaard
Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
November 9, 2021
Assignee:
FRESENIUS KABI IPSUM S.R.L
Inventors:
Antonio Ricci, Jacopo Zanon, Walter Cabri, Ivan Guryanov, Andrea Orlandin, Barbara Biondi, Fernando Formaggio, Dario Visentini
Abstract: The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.
Type:
Grant
Filed:
August 19, 2016
Date of Patent:
November 2, 2021
Assignee:
GENOIMMUNE THERAPEUTICS CO., LTD.
Inventors:
Yong Hou, Shuntao Luo, Ting An, Xiumei Lin, Bo Li, Guanglei Li
Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.
Type:
Grant
Filed:
June 4, 2020
Date of Patent:
November 2, 2021
Assignee:
Apeptico Forschung UND Entwicklung GMBH
Inventors:
Bernhard Fischer, Rudolf Lucas, Hendrik Fischer
Abstract: Provided herein are anti-inflammatory nanofibers and methods of use thereof. In particular methods are provided for the use of anti-inflammatory nanofibers in the promotion of tissue (e.g., urinary bladder tissue) regeneration.
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
Abstract: Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses.
Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.
Type:
Grant
Filed:
August 10, 2020
Date of Patent:
October 26, 2021
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
Abstract: The present invention relates to a method for preventing and treating pulmonary fibrosis, comprising administering an effective amount of plasminogen to a subject.
Abstract: The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
October 26, 2021
Assignee:
Eli Lilly and Company
Inventors:
Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.
Type:
Grant
Filed:
December 27, 2019
Date of Patent:
October 19, 2021
Assignees:
The Board of Trustees of the California State University, California State University, Los Angeles
Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
October 19, 2021
Assignee:
ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
Abstract: The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
October 19, 2021
Assignees:
Clemson University Research Foundation, MUSC Foundation for Research Development
Inventors:
Ying Mei, Jia Jia, Chung-Jen James Chou
Abstract: The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.
Type:
Grant
Filed:
August 26, 2015
Date of Patent:
October 19, 2021
Assignee:
Amgen Inc.
Inventors:
Jason C. O'Neill, Randal R. Ketchem, Taeweon Lee, Vishnu Chintalgattu, Jennitte Leann Stevens
Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
October 12, 2021
Assignee:
CSL Behring Lengnau AG
Inventors:
Anne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
Abstract: Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1: R1-Nle4-c[Xaa5-Yaa6-(NMe)D-Nal(2?)7-Arg8-Trp9-(NMe)Zaa10]-R2. R1 can be an acetyl, a glycosylated amino acid, —CO—(CH2)nCH3, or —CO—(CH2)nCF3 with n ranging from 1 to 6. R2 can be an —CONH2, —COOH, or —CH2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
September 21, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.